Higher ocrelizumab doses improve the benefit-risk profile among patients with relapsing multiple sclerosis treated with it for up to 10 years.

Efficacy of treatment is maintained during the switch from IV anti-CD20 therapies to ofatumumab in relapsing MS regardless of race/ethnicity.

Ocrevus as a first-line treatment for early relapsing MS is better at delaying disease progression than starting with a less ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase II results of orelabrutinib ...

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis – Vidofludimus Calcium’s Activation of Nurr1 Reduces ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Discover a study where patients initially receiving placebo experienced notable improvement after switching to tildrakizumab.

By Mongabay.com The Madras hedgehog, found only in southern India, is considered a species of least concern on the IUCN Red ...

Conference/Study26.02.2025 / 12:30 CET/CESTThe issuer is solely responsible for the content of this announcement. Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting ...